Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 1/2006

01-02-2006

New thoughts on the pathophysiology of osteoarthritis: One more step toward new therapeutic targets

Authors: Johanne Martel-Pelletier, PhD, Daniel Lajeunesse, PhD, Hassan Fahmi, PhD, Ginette Tardif, PhD, Jean-Pierre Pelletier, MD

Published in: Current Rheumatology Reports | Issue 1/2006

Login to get access
Metadata
Title
New thoughts on the pathophysiology of osteoarthritis: One more step toward new therapeutic targets
Authors
Johanne Martel-Pelletier, PhD
Daniel Lajeunesse, PhD
Hassan Fahmi, PhD
Ginette Tardif, PhD
Jean-Pierre Pelletier, MD
Publication date
01-02-2006
Publisher
Current Medicine Group
Published in
Current Rheumatology Reports / Issue 1/2006
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-006-0022-6

Other articles of this Issue 1/2006

Current Rheumatology Reports 1/2006 Go to the issue

Invited Commentary

High-resolution molecular analysis for research in rheumatology

Clinical Trials Report

Low- dose prednisolone in early rheumatoid arthritis

OriginalPaper

Managing osteoarthritis pain when your patient fails simple analgesics and NSAIDs and is not a candidate for surgery

OriginalPaper

Idiopathic hypercalciuria

OriginalPaper

Imaging osteoarthritis: Magnetic resonance imaging versus x-ray

OriginalPaper

Osteoprotegerin as a potential therapy for osteoporosis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits